Clinical Research Directory
Browse clinical research sites, groups, and studies.
Whole Versus Partial Gland Boost During Prostate SBRT
Sponsor: University of Nebraska
Summary
This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
Official title: A Phase 2/3 Randomized Trial of Whole Versus Partial Gland Boost During Prostate Stereotactic Body Radiotherapy (SBRT)
Key Details
Gender
MALE
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
186
Start Date
2026-07-25
Completion Date
2035-08-25
Last Updated
2026-05-13
Healthy Volunteers
No
Conditions
Interventions
Prostate stereotactic body radiotherapy with whole gland boost
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost
Prostate stereotactic body radiotherapy with DIL boost
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.
Locations (1)
Fred & Pamela Buffet Cancer Center
Omaha, Nebraska, United States